A prospective, randomized, masked and controlled trial of intravitreal bevacizumab (Avastin®) for central retinal vein occlusion (CRVO).

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-006265-93-SE

Enrollment

Registered

2008-10-23

Start date

2009-03-11

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central retinal vein occlusion (CRVO) is a sight-threatening ocular condition without efficient treatment.

Interventions

Trade Name: Avastin ® Product Name: Avastin® Pharmaceutical Form: Injection* INN or Proposed INN: Bevacizumab Other descriptive name: BEVACIZUMABUM

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CRVO with a duration of 6 months or less. Visual acuity between 0.025-0.4 Snellen (5-67 ETDRS letters). Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Previous CRVO treatment in study eye. Duration > 6 months. Previous treatment in study eye with anti-VEGF agents.

Design outcomes

Primary

Measure	Time frame
Main Objective: To study whether intravitreal bevacizumab (Avastin®) results in significant visual improvement in patients with CRVO as compared to the natural course of the disease. ;Secondary Objective: To study whether intravitreal bevacizumab (Avastin®) results in significantly decreased macular edema, reduced laser scatter treatments and decreased iris rubeosis in patients with CRVO as compared to the natural course of the disease. ;Primary end point(s): The proportion of patients gaining 15 ETDRS letters or more after 6 months.	—

Measure

Time frame

Main Objective: To study whether intravitreal bevacizumab (Avastin®) results in significant visual improvement in patients with CRVO as compared to the natural course of the disease. ;Secondary Objective: To study whether intravitreal bevacizumab (Avastin®) results in significantly decreased macular edema, reduced laser scatter treatments and decreased iris rubeosis in patients with CRVO as compared to the natural course of the disease. ;Primary end point(s): The proportion of patients gaining 15 ETDRS letters or more after 6 months.

—

Countries

Sweden

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026